Category: Clinical Trials

In the United States, only 6.3% of cancer patients participate in clinical trials1 and 60% of eligible cancer patients are NOT presented with clinical trials as treatment options2. Visit 1104Health, we’re on a mission to simplify and expedite the clinical trial matching process for all. Whether you’re a cancer patient or referring physician looking for the…

Phase II results presented at the European Society for Medical Oncology (ESMO) 2012 Congress showed a 3.6-month improvement in progression-free survival (PFS) for patients receiving both the BRAF inhibitor dabrafenib and trametinib, a MEK inhibitor, compared to those receiving dabrafenib alone. PFS was 9.4 months for patients who received dabrafenib plus trametinib compared to 5.8…

Two drugs being evaluated by the FDA slowed the development of treatment resistance in persons with metastatic malignant melanoma positive for the BRAF protein. http://www.oncologynurseadvisor.com/dual-drug-therapy-delayed-treatment-resistance-in-melanoma/article/264688/http://www.oncologynurseadvisor.com/dual-drug-therapy-delayed-treatment-resistance-in-melanoma/article/264688/

Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced patients remains below 20%.There are today 242 companies plus partners developing 273 drugs targeting melanoma in development. In addition, there are…

ABSTRACT: “Targeted therapy” is becoming the centerpiece of current therapeutic strategies, and is often mentioned as the desirable direction for future progress. Why and how it is replacing past approaches in the management of solid tumors is the subject of this two-part overview. Here, in Part I, we describe areas where major inroads were initially…

A summary of the phase III BREAK-3 trial comparing the BRAF inhibitor dabrafenib with the chemotherapy agent dacarbazine (DTIC). Patients taking dabrafenib had an improved progression-free survival (PFS) of 2.4 months compared with patients receiving chemotherapy. Read more…

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Adoptive cell transfer therapies (ACTs) with cytotoxic T cells that target melanocytic antigens can achieve remissions in patients with metastatic melanomas, but tumours frequently relapse.